RecruitingDepression
Study on Allopregnanolone and Depression in Women Across the Menopause Transition
Eligible age
40–60 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.
Sponsor: Beth Israel Deaconess Medical Center
You may qualify if…
- ✓ Healthy women ages 40 to 60 years in the menopause transition
- ✓ Depressive symptoms
- ✓ Psychotropic medications are allowed if the dose is stable prior to screening and throughout the study
- ✓ Able to read Arabic numerals and perform simple arithmetic
- ✓ Able to provide written informed consent
You may not qualify if…
- ✕ Systemic hormone therapy
- ✕ Contraindicated medications with pregnenolone
- ✕ Systemic corticosteroid
- ✕ Other psychiatric illnesses that are considered to be primary
- ✕ Current suicidal ideation
- ✕ Active substance use disorders
- ✕ Unstable medical conditions
- ✕ Obstructive sleep apnea or other primary sleep disorders
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT06238700 · last updated 2026-08-26